Literature DB >> 19570825

Skin inflammation is not sufficient to break tolerance induced against a novel antigen.

Martin Holcmann1, Patrizia Stoitzner, Barbara Drobits, Petra Luehrs, Georg Stingl, Nikolaus Romani, Dieter Maurer, Maria Sibilia.   

Abstract

Depending on the cellular and molecular microenvironment, immune responses generated by skin-associated lymphoid tissues can lead to protective immunity against pathogens or to tolerance. In this study, we investigated immune responses to an Ag expressed de novo in adult skin under homeostatic conditions by generating transgenic mice producing the Ag Ova in a Cre-inducible manner in keratinocytes. Expression of Ova was induced in adult mice with a tamoxifen-inducible K5-CreER transgenic line. Although Ova was efficiently expressed by keratinocytes and presented by Langerhans cells after Cre-mediated transgene recombination, adult transgenic mice did not develop any obvious autoimmune disease symptoms like hair or weight loss. Ag-specific T cells were activated after Ova expression as indicated by up-regulation of CD44 and CD69. After in vitro restimulation Ova-specific T cells showed reduced IFN-gamma production suggesting induction of tolerance after Ova expression in the skin. After transfer into Ova-expressing mice, naive OT-1 T cells transiently proliferated in skin-draining lymph nodes, infiltrated the skin but did not cause disease. Topical application of danger signals at the time of Ova induction did also not induce autoimmune disease. The unresponsiveness of Ag-specific T cells after induction of Ova expression could only be circumvented by simultaneous priming with CpG-matured, bone marrow-derived dendritic cells. Our data suggest that low amount of Ag expressed in the induction phase of the immune response results in tolerance even in the presence of danger signals and thereby helps to preserve homeostasis in the skin under normal and pathologic conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570825     DOI: 10.4049/jimmunol.0713351

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Neoantigen Expression in Steady-State Langerhans Cells Induces CTL Tolerance.

Authors:  Helen Strandt; Douglas Florindo Pinheiro; Daniel H Kaplan; Dagmar Wirth; Iris Karina Gratz; Peter Hammerl; Josef Thalhamer; Angelika Stoecklinger
Journal:  J Immunol       Date:  2017-07-24       Impact factor: 5.422

2.  A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Authors:  Salvatore Fiorenza; Tony J Kenna; Iain Comerford; Shaun McColl; Raymond J Steptoe; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2012-11-09       Impact factor: 5.422

Review 3.  Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin.

Authors:  Nikolaus Romani; Björn E Clausen; Patrizia Stoitzner
Journal:  Immunol Rev       Date:  2010-03       Impact factor: 12.988

4.  Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.

Authors:  Barbara Drobits; Martin Holcmann; Nicole Amberg; Melissa Swiecki; Roland Grundtner; Martina Hammer; Marco Colonna; Maria Sibilia
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

Review 5.  Antigen presentation by Langerhans cells.

Authors:  Botond Z Igyártó; Daniel H Kaplan
Journal:  Curr Opin Immunol       Date:  2012-12-12       Impact factor: 7.486

6.  TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo.

Authors:  Jing Wu; Shuang Li; Yang Yang; Shan Zhu; Mingyou Zhang; Yuan Qiao; Yong-Jun Liu; Jingtao Chen
Journal:  Oncotarget       Date:  2017-02-14

7.  Specific roles for dendritic cell subsets during initiation and progression of psoriasis.

Authors:  Elisabeth Glitzner; Ana Korosec; Patrick M Brunner; Barbara Drobits; Nicole Amberg; Helia B Schonthaler; Tamara Kopp; Erwin F Wagner; Georg Stingl; Martin Holcmann; Maria Sibilia
Journal:  EMBO Mol Med       Date:  2014-10       Impact factor: 12.137

8.  Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance.

Authors:  Vincent Flacher; Christoph H Tripp; David G Mairhofer; Ralph M Steinman; Patrizia Stoitzner; Juliana Idoyaga; Nikolaus Romani
Journal:  EMBO Mol Med       Date:  2014-09       Impact factor: 12.137

Review 9.  Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses.

Authors:  Björn E Clausen; Patrizia Stoitzner
Journal:  Front Immunol       Date:  2015-10-22       Impact factor: 7.561

Review 10.  Targeting dendritic cells: a promising strategy to improve vaccine effectiveness.

Authors:  Christophe Macri; Claire Dumont; Angus Pr Johnston; Justine D Mintern
Journal:  Clin Transl Immunology       Date:  2016-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.